Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study

Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study

301565

Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study

RAPIDe-1, a Phase 2 clinical trial testing Pharvaris’ investigational oral therapy PHVS416 as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will expand its enrollment this year to include patients in the U.S. “We are encouraged by positive feedback from clinical sites and look forward to expanding [RAPIDe-1] to provide the opportunity for U.S. patients to participate,” Berndt Modig, co-founder and CEO of Pharvaris, said in a press release. The company said…

You must be logged in to read/download the full post.